Report Detail
Global Drug Repurposing Market Insights, Forecast to 2025
- RnM3518521 |
- 12 June, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Pharma & Healthcare
Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned. National Institute of Health (NIH), U.S. Department of Health defines drug repurposing as discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside. Drug repurposing opens up various opportunities to answer current unmet medical needs to come up with cost-effective solutions to expensive drug development process. Repurposing or re-profiling of drugs which are suspended due to lack of efficacy or specificity can be a good start over for further development for new indication. Finding new indications for already studied drugs can benefit patients by getting quick access to new treatment choices and also to developer by saving time and money while maintaining its original IP protection. For many expensive indications such as cancer, scrutinizing for anti-cancer activity among dozens of off-patent drugs that have already established their safety is a powerful method opted by majority of the big pharma companies. However, repurposing is not a new strategy and there are bunch of drugs which are repositioned or repurposed, some of them are Raloxifene (approved for treatment of osteoporosis in 2007, originally indicated for breast cancer treatment), Thalidomide (repositioned for use in treatment of leprosy and multiple myeloma in 2006), Rapamycin (repurposed in 1999 for prevention of organ transplant rejection), Sildenafil (originally approved for erectile dysfunction and recently got approved for treatment of angina) and many others.
Requirement of low investment of time and money in the drug development is the prime advantage of drug repurposing and majority of the drugs in pipeline of major pharmaceutical companies are thus adopt this method. Some of the factors accelerating the drug repurposing activities include sunk research cost, ready availably of bioavailability, pharmacology, toxicity profile & pharmacokinetics data, well established manufacturing protocol etc.; which are expected to drive the global drug repurposing market. There are thousands of failed molecules shelved into the drug libraries, which hold vast potential to reposition. Whereas, limited access chemical structure data of drug molecules, lack of funding etc. are some of the factors limiting the growth of global drug repurposing market.
The global Drug Repurposing market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Drug Repurposing market based on company, product type, end user and key regions.
This report studies the global market size of Drug Repurposing in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Drug Repurposing in these regions.
This research report categorizes the global Drug Repurposing market by top players/brands, region, type and end user. This report also studies the global Drug Repurposing market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Astellas Pharma
Biovista
Novartis
AbbVie
Pfizer
Allergan
NuMedii
Market size by Product
Oncology
CNS Diseases
Neurodegenerative Diseases
Others
Market size by End User
Hospitals
Ambulatory Surgical Centers
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Drug Repurposing market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Drug Repurposing market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Drug Repurposing companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Drug Repurposing submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Drug Repurposing are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Drug Repurposing market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Drug Repurposing Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Drug Repurposing Market Size Growth Rate by Product
- 1.4.2 Oncology
- 1.4.3 CNS Diseases
- 1.4.4 Neurodegenerative Diseases
- 1.4.5 Others
- 1.5 Market by End User
- 1.5.1 Global Drug Repurposing Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Ambulatory Surgical Centers
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Drug Repurposing Market Size
- 2.1.1 Global Drug Repurposing Revenue 2014-2025
- 2.1.2 Global Drug Repurposing Sales 2014-2025
- 2.2 Drug Repurposing Growth Rate by Regions
- 2.2.1 Global Drug Repurposing Sales by Regions
- 2.2.2 Global Drug Repurposing Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Drug Repurposing Sales by Manufacturers
- 3.1.1 Drug Repurposing Sales by Manufacturers
- 3.1.2 Drug Repurposing Sales Market Share by Manufacturers
- 3.1.3 Global Drug Repurposing Market Concentration Ratio (CR5 and HHI)
- 3.2 Drug Repurposing Revenue by Manufacturers
- 3.2.1 Drug Repurposing Revenue by Manufacturers (2014-2019)
- 3.2.2 Drug Repurposing Revenue Share by Manufacturers (2014-2019)
- 3.3 Drug Repurposing Price by Manufacturers
- 3.4 Drug Repurposing Manufacturing Base Distribution, Product Types
- 3.4.1 Drug Repurposing Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Drug Repurposing Product Type
- 3.4.3 Date of International Manufacturers Enter into Drug Repurposing Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Drug Repurposing Sales by Product
- 4.2 Global Drug Repurposing Revenue by Product
- 4.3 Drug Repurposing Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Drug Repurposing Breakdown Data by End User
6 North America
- 6.1 North America Drug Repurposing by Countries
- 6.1.1 North America Drug Repurposing Sales by Countries
- 6.1.2 North America Drug Repurposing Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Drug Repurposing by Product
- 6.3 North America Drug Repurposing by End User
7 Europe
- 7.1 Europe Drug Repurposing by Countries
- 7.1.1 Europe Drug Repurposing Sales by Countries
- 7.1.2 Europe Drug Repurposing Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Drug Repurposing by Product
- 7.3 Europe Drug Repurposing by End User
8 Asia Pacific
- 8.1 Asia Pacific Drug Repurposing by Countries
- 8.1.1 Asia Pacific Drug Repurposing Sales by Countries
- 8.1.2 Asia Pacific Drug Repurposing Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Drug Repurposing by Product
- 8.3 Asia Pacific Drug Repurposing by End User
9 Central & South America
- 9.1 Central & South America Drug Repurposing by Countries
- 9.1.1 Central & South America Drug Repurposing Sales by Countries
- 9.1.2 Central & South America Drug Repurposing Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Drug Repurposing by Product
- 9.3 Central & South America Drug Repurposing by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Drug Repurposing by Countries
- 10.1.1 Middle East and Africa Drug Repurposing Sales by Countries
- 10.1.2 Middle East and Africa Drug Repurposing Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Drug Repurposing by Product
- 10.3 Middle East and Africa Drug Repurposing by End User
11 Company Profiles
- 11.1 Astellas Pharma
- 11.1.1 Astellas Pharma Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Astellas Pharma Drug Repurposing Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Astellas Pharma Drug Repurposing Products Offered
- 11.1.5 Astellas Pharma Recent Development
- 11.2 Biovista
- 11.2.1 Biovista Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Biovista Drug Repurposing Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Biovista Drug Repurposing Products Offered
- 11.2.5 Biovista Recent Development
- 11.3 Novartis
- 11.3.1 Novartis Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Novartis Drug Repurposing Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Novartis Drug Repurposing Products Offered
- 11.3.5 Novartis Recent Development
- 11.4 AbbVie
- 11.4.1 AbbVie Company Details
- 11.4.2 Company Business Overview
- 11.4.3 AbbVie Drug Repurposing Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 AbbVie Drug Repurposing Products Offered
- 11.4.5 AbbVie Recent Development
- 11.5 Pfizer
- 11.5.1 Pfizer Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Pfizer Drug Repurposing Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Pfizer Drug Repurposing Products Offered
- 11.5.5 Pfizer Recent Development
- 11.6 Allergan
- 11.6.1 Allergan Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Allergan Drug Repurposing Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Allergan Drug Repurposing Products Offered
- 11.6.5 Allergan Recent Development
- 11.7 NuMedii
- 11.7.1 NuMedii Company Details
- 11.7.2 Company Business Overview
- 11.7.3 NuMedii Drug Repurposing Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 NuMedii Drug Repurposing Products Offered
- 11.7.5 NuMedii Recent Development
12 Future Forecast
- 12.1 Drug Repurposing Market Forecast by Regions
- 12.1.1 Global Drug Repurposing Sales Forecast by Regions 2019-2025
- 12.1.2 Global Drug Repurposing Revenue Forecast by Regions 2019-2025
- 12.2 Drug Repurposing Market Forecast by Product
- 12.2.1 Global Drug Repurposing Sales Forecast by Product 2019-2025
- 12.2.2 Global Drug Repurposing Revenue Forecast by Product 2019-2025
- 12.3 Drug Repurposing Market Forecast by End User
- 12.4 North America Drug Repurposing Forecast
- 12.5 Europe Drug Repurposing Forecast
- 12.6 Asia Pacific Drug Repurposing Forecast
- 12.7 Central & South America Drug Repurposing Forecast
- 12.8 Middle East and Africa Drug Repurposing Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Drug Repurposing Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Drug Repurposing . Industry analysis & Market Report on Drug Repurposing is a syndicated market report, published as Global Drug Repurposing Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Drug Repurposing market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
